Header Logo

Connection

Andrew Ambrosy to Double-Blind Method

Back to Details
This is a "connection" page, showing publications Andrew Ambrosy has written about Double-Blind Method.
Andrew Ambrosy
Connection Strength
0.902
Double-Blind Method
  1. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
    View in: PubMed
    Score: 0.184
  2. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). Am J Cardiol. 2017 07 01; 120(1):98-105.
    View in: PubMed
    Score: 0.146
  3. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
    View in: PubMed
    Score: 0.136
  4. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
    View in: PubMed
    Score: 0.045
  5. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. Circ Heart Fail. 2020 05; 13(5):e006758.
    View in: PubMed
    Score: 0.045
  6. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
    View in: PubMed
    Score: 0.041
  7. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail. 2018 12; 5(6):1035-1043.
    View in: PubMed
    Score: 0.040
  8. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
    View in: PubMed
    Score: 0.038
  9. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2018 02; 20(2):304-314.
    View in: PubMed
    Score: 0.038
  10. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
    View in: PubMed
    Score: 0.033
  11. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
    View in: PubMed
    Score: 0.028
  12. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013 Feb 05; 61(5):571-9.
    View in: PubMed
    Score: 0.027
  13. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol. 2013 Feb 15; 111(4):574-81.
    View in: PubMed
    Score: 0.027
  14. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec; 164(6):884-92.e2.
    View in: PubMed
    Score: 0.027
  15. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct; 32(20):2563-72.
    View in: PubMed
    Score: 0.024
  16. Unilateral groin surgery in children: will the addition of an ultrasound-guided ilioinguinal nerve block enhance the duration of analgesia of a single-shot caudal block? Paediatr Anaesth. 2009 Sep; 19(9):892-8.
    View in: PubMed
    Score: 0.021

© 2024 Kaiser Permanente